N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity

in Journal of Endocrinology
Authors:
BD Green
Search for other papers by BD Green in
Current site
Google Scholar
PubMed
Close
,
MH Mooney
Search for other papers by MH Mooney in
Current site
Google Scholar
PubMed
Close
,
VA Gault
Search for other papers by VA Gault in
Current site
Google Scholar
PubMed
Close
,
N Irwin
Search for other papers by N Irwin in
Current site
Google Scholar
PubMed
Close
,
CJ Bailey
Search for other papers by CJ Bailey in
Current site
Google Scholar
PubMed
Close
,
P Harriott
Search for other papers by P Harriott in
Current site
Google Scholar
PubMed
Close
,
B Greer
Search for other papers by B Greer in
Current site
Google Scholar
PubMed
Close
,
FP O'Harte
Search for other papers by FP O'Harte in
Current site
Google Scholar
PubMed
Close
, and
PR Flatt
Search for other papers by PR Flatt in
Current site
Google Scholar
PubMed
Close
View More View Less
Free access

Glucagon-like peptide-1(7-36)amide (GLP-1) possesses several unique and beneficial effects for the potential treatment of type 2 diabetes. However, the rapid inactivation of GLP-1 by dipeptidyl peptidase IV (DPP IV) results in a short half-life in vivo (less than 2 min) hindering therapeutic development. In the present study, a novel His(7)-modified analogue of GLP-1, N-pyroglutamyl-GLP-1, as well as N-acetyl-GLP-1 were synthesised and tested for DPP IV stability and biological activity. Incubation of GLP-1 with either DPP IV or human plasma resulted in rapid degradation of native GLP-1 to GLP-1(9-36)amide, while N-acetyl-GLP-1 and N-pyroglutamyl-GLP-1 were completely resistant to degradation. N-acetyl-GLP-1 and N-pyroglutamyl-GLP-1 bound to the GLP-1 receptor but had reduced affinities (IC(50) values 32.9 and 6.7 nM, respectively) compared with native GLP-1 (IC(50) 0.37 nM). Similarly, both analogues stimulated cAMP production with EC(50) values of 16.3 and 27 nM respectively compared with GLP-1 (EC(50) 4.7 nM). However, N-acetyl-GLP-1 and N-pyroglutamyl-GLP-1 exhibited potent insulinotropic activity in vitro at 5.6 mM glucose (P<0.05 to P<0.001) similar to native GLP-1. Both analogues (25 nM/kg body weight) lowered plasma glucose and increased plasma insulin levels when administered in conjunction with glucose (18 nM/kg body weight) to adult obese diabetic (ob/ob) mice. N-pyroglutamyl-GLP-1 was substantially better at lowering plasma glucose compared with the native peptide, while N-acetyl-GLP-1 was significantly more potent at stimulating insulin secretion. These studies indicate that N-terminal modification of GLP-1 results in DPP IV-resistant and biologically potent forms of GLP-1. The particularly powerful antihyperglycaemic action of N-pyroglutamyl-GLP-1 shows potential for the treatment of type 2 diabetes.